The Founders District in West Houston has an NFT investment opportunity. Rendering via foundersdistrict.com

Developers are turning to blockchain technology to help finance a new indoor-outdoor bar at Houston’s Founders District innovation campus.

Under the umbrella of the Powder Keg Collective, the Powder Keg bar is selling non-fungible tokens (NFTs) to finance construction and operation of its 14,000-square-foot expansion. NFTs, similar to cryptocurrencies, are stored on a blockchain and represent ownership of a unique asset.

The new venue will be at 1300 Brittmoore Rd., near the existing Powder Keg bar and The Cannon West Houston entrepreneurial hub. Aside from catering to everyday patrons, the venue will host community events, festivals, private events, and concerts.

Buyers of the Powder Keg NFTs will be entitled to gain proceeds from the development, and will receive beer discounts, access to VIP events, and other privileges.

“These utility NFTs provide owners with tangible financial value and membership in a real estate club, not empty hype,” Mark Toon, co-owner of the Powder Keg, The Cannon and the Founders District, says in a news release.

“The Powder Keg Collective is another way we’re building community around technology, demystifying it, and bringing together Houstonians — whether they’re investors, NFT collectors, crypto-enthusiasts, or people who just want a stake in their neighborhood bar.”

On the Ethereum blockchain platform, the collective will sell 2,361 tokens ranging in price from $250 to $500,000 each. Tokens can be purchased with cryptocurrencies or U.S. dollars. The venue itself will accept the same two payment methods.

The Powder Keg is planning an expansion. Photo courtesy

The Cannon's new building is 88 percent leased and ready for move in. Courtesy of The Cannon

Photos: The Cannon unveils its 120,000-square-foot startup hub in West Houston

Homecoming

The Cannon is finally getting to move its 150 startups and partners into its 120,000-square-foot campus in West Houston.

The original plan was to open in March, but construction, which began in April 2018, faced a series of setbacks due to weather. Current grand opening celebration plans are expected to be in September.

The flagship building is just the first step developing the campus, which is dubbed the Founders District.

"Our team has worked tirelessly to build this community over the past eighteen months, and we are incredibly proud to see our vision coming to life with the completion of this building," says The Cannon's CEO Lawson Gow in a news release. "The work isn't over though, and The Cannon will continue to grow our network of resources and locations to cater to the needs of Houston's growing entrepreneurial community." (Gow is the son of David Gow, owner of InnovationMap's parent company Gow Media.)

The building is currently 88 percent leased. Cannon Ventures, the company's investor group, will operate out of the new building, as will Capital Factory's Houston outpost. Austin-based Capital Factory, a statewide startup accelerator announced it would have its Houston operations at The Cannon in May. Since then, the company hired two Houston-based employees to run the programming.

According to the release, The Cannon will continue to grow its community relations for a "full suite" of partners. Houston-based investment fund Work America Capital, which led The Cannon's initial fundraising round, will also be joining The Cannon's community in the new building.

"It has been incredible to watch The Cannon's exceptional growth from inception two years ago to the vibrant community they've built today," says Mark Toon, managing partner of Work America Capital, in the release. "We can't wait to see the progress first-hand as The Cannon continues to establish themselves as a leader in building entrepreneurial communities."

The Cannon previously operated out of a 20,000-square-foot adjacent building called "The Waiting Room," which will be torn down and the space will be used as a part of the bigger Founders District plan.

The Cannon's new space will feature:

  • A 16-TV video wall
  • Outdoor courtyard
  • Movie theater
  • Snacks, coffee, and beer
  • Office needs, such as printers, scanners, and mail services
  • Showers
  • 24/7 accessibility
  • Professional and social events are organized on an ongoing basis for the community
  • Private event hosting for both members and non-members

Spacious setting

Courtesy of The Cannon

The Cannon is currently 88 percent leased.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.